EC

Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs Development Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022 - 10:06am
Health, General Health, Molecule, Research and development, History, R, Research, News, Route of administration, Decision-making, EC, Key, Coronaviridae, RNA, Development of the human body, Mall of America, Therapy, Administration, Human, RNA polymerase II, Product description, Vaccine

The "Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Human SARS Coronavirus 2 RNA Dependent RNA Polymerase (RdRp or EC 2.7.7.48) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Human SARS Coronavirus 2 RNA Dependent RNA Polymerase (RdRp or EC 2.7.7.48) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Human SARS Coronavirus 2 RNA Dependent RNA Polymerase (RdRp or EC 2.7.7.48) targeted therapeutics development and features dormant and discontinued projects.

Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement

Retrieved on: 
Monday, May 16, 2022 - 6:15am
CpG, Royal commission, Severe acute respiratory syndrome coronavirus 2, Company, Saint-Herblain, European Commission, Nasdaq, European Medicines Agency, Webcast, Health, Infection, Vaccine, Emergency Use Authorization, Vero, COVID-19, Ministry, Health care, EC, APA, Vaccination, United Kingdom, Committee for Medicinal Products for Human Use, National Health Regulatory Authority, CHMP, EMA, United Arab Emirates, Technology, Lyme disease, Chikungunya, 1018, Medication, Committee, European Directive on Traditional Herbal Medicinal Products, Medical device, VLA2001

Saint-Herblain (France), May 16, 2022 Valneva SE , a specialty vaccine company, today announced that it has received a notice from the European Commission (EC) of intent to terminate the advance purchase agreement (APA) for Valnevas inactivated whole-virus COVID-19 vaccine candidate VLA2001.

Key Points: 
  • Saint-Herblain (France), May 16, 2022 Valneva SE , a specialty vaccine company, today announced that it has received a notice from the European Commission (EC) of intent to terminate the advance purchase agreement (APA) for Valnevas inactivated whole-virus COVID-19 vaccine candidate VLA2001.
  • Thomas Lingelbach, Chief Executive Officer of Valneva, commented, the EC decision is regrettable especially as we continue to receive messages from Europeans who are looking for a more traditional vaccine solution.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.
  • The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases.

Holding(s) in Company

Retrieved on: 
Friday, May 13, 2022 - 6:05pm
Central Bank of the Republic of Turkey, Ix, Exercise, Disclosure, Person, LEI, Vii, Council Implementing Regulation (EU) No. 282/2011, EC, Intention, Life, Central bank, Acquisition, Letter, Security (finance), Auction, Medical device, Transparency, EU, Regulation

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.

Key Points: 
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC).
  • xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

Day One Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 12, 2022 - 9:30pm
Royal commission, Physician, Ageing, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Research, U.S. Securities and Exchange Commission, European Commission, Adolescence, Glioma, Patient, Investment, Health, Clinical trial, Brain, D, COVID-19, Adult, EC, Orphan drug, MEK, FDA, Breakthrough therapy, SAN, MAPK, CST, Booth, Forward-looking statement, Day One, Safety, RAF, NDA, Drug development, LinkedIn, Twitter, Security (finance), GLOBE, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced financial results for the first quarter of 2022 and highlighted recent corporate achievements.

Key Points: 
  • Initial data from FIREFLY-1, a pivotal Phase 2 clinical trial of tovorafenib in relapsed pLGG, is expected in June 2022.
  • Day One anticipates releasing topline results from the fully-enrolled pivotal study in the first quarter of 2023.
  • Pending positive results from FIREFLY-1, Day One anticipates filing a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2023.
  • Day One plans to initiate a pivotal Phase 3 clinical trial (FIREFLY-2) evaluating tovorafenib as a front-line therapy in pLGG in the second quarter of 2022.

500+ Gather in Amsterdam for Euro Convergence, RAPS’ Largest-Ever European Event

Retrieved on: 
Thursday, May 12, 2022 - 8:11pm
RAPS, Royal commission, NAMSA, Education, Food, US Food Sovereignty Alliance, PAREXEL, Medicines and Healthcare products Regulatory Agency, Â, European Commission, European Medicines Agency, IVD, Health, MHRA, BSI, Health care, EC, Research, FDA, Industry, EMA, Euro, RAC, Medication, Publication, GLOBE, Video game, Medical device, Security (finance), EU, Swissmedic, MD

Euro Convergence is the premier annual event for European regulatory professionals.

Key Points: 
  • Euro Convergence is the premier annual event for European regulatory professionals.
  • This years Euro Convergence also offered the European regulatory community a long-awaited opportunity to once again meet in person to discuss issues, share ideas and network.
  • The European regulatory community is still navigating extensive changes to EU regulations even as we continue to address urgent pandemic-related healthcare needs.
  • The fact that it has been RAPS largest-ever European conference is a testament to the vibrance and dedication of the regulatory community.

H2O Innovation Reports Record High Revenues of $51.9 M

Retrieved on: 
Thursday, May 12, 2022 - 1:00pm
Calumet Specialty Products Partners, EBITDA, O&M, Depreciation, GMP, Sick leave, Corporation, Insurance, USD, COVID-19, EC, TSX, Pressure, SG, JCO, WTS, GAAP, Acquisition, Growth, Pharmaceutical industry, Online gambling

QUEBEC CITY, May 12, 2022 (GLOBE NEWSWIRE) -- (TSX: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) announces its financial results for the third quarter of fiscal year 2022 ended March 31, 2022.

Key Points: 
  • In the last twelve months, the O&M business pillar gained four new projects as well as scope expansions.
  • Generally, start-up of new projects begins at lower gross profit margins because of training and initial setup, after which margins grow progressively.
  • H2O Innovations business model relies on three different business pillars enabling it to reduce the volatility of the Corporations profitability through diversification.
  • Even though adjusted EBITDA is a non-IFRS measure, it is used by management to make operational and strategic decisions.

Dalata Hotel Group PLC: Holding(s) in Company

Retrieved on: 
Tuesday, May 10, 2022 - 8:06am
Council Implementing Regulation (EU) No. 282/2011, Central Bank of the Republic of Turkey, Disclosure, Acquisition, Person, Ix, Letter, EC, Intention, Vii, Central bank, LEI, Life, Exercise, Security (finance), Auction, Medical device, EU, Regulation, Transparency

In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

Key Points: 
  • In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]
    i.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC).

Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe

Retrieved on: 
Monday, May 9, 2022 - 11:30am
LHRH, European Economic Area, Endometriosis, Female, SEC, Royal commission, Twitter, Woman, Prostate, NYSE, European Commission, Patient, Partnership, Risk, FDA, Sidley Austin, Regulation of tobacco by the U.S. Food and Drug Administration, New Drug Application, LinkedIn, Uterine fibroid, Roivant Sciences, Private Securities Litigation Reform Act, Urban economics, Pregnancy, Gonadotropin-releasing hormone, Injection, Infertility, Prostate cancer, Cyprus Securities and Exchange Commission, Medicines and Healthcare products Regulatory Agency, Growth, Man, Calendar, GLOBE, MHRA, Food, Radiation, Testosterone, Cancer, Adult, EC, Pharmaceutical industry, Medical imaging, Accord

We are proud to launch ORGOVYX in Europe, as an addition to our specialty brand offerings, said Binish Chudgar, Managing Director of Accord.

Key Points: 
  • We are proud to launch ORGOVYX in Europe, as an addition to our specialty brand offerings, said Binish Chudgar, Managing Director of Accord.
  • Accord currently supplies around 1 in 3 injectable oncology medicines in Europe and this agreement underpins our commitment to patients with cancer and our continued investment in novel therapies.
  • With over 1.9 million men living with prostate cancer in Europe, our partnership with Myovant will provide men living with hormone-sensitive advanced prostate cancer a new oral treatment option.
  • ORGOVYX (relugolix, 120 mg) is indicated in Europe for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Murata Manufacturing: 3-in-1 Soil Sensors Help Maximize Crop Yield and Quality in Smart Agriculture

Retrieved on: 
Monday, May 9, 2022 - 4:00am
Agriculture, Natural Resources, Other Manufacturing, Hardware, Data Management, Technology, Manufacturing, Mobile, Wireless, Lake, Dust, Sustainable Development Goals, Water, Â, Algorithm, RS485, Soil, Electrode, Temperature, Farmer, ISIN, River, AA, EC, Uncertainty, UART, IP68, Fertilizer, Murata, Multimedia

Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) has introduced a highly accurate three-in-one soil sensor for data-driven sustainable agriculture.

Key Points: 
  • Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) has introduced a highly accurate three-in-one soil sensor for data-driven sustainable agriculture.
  • By simultaneously monitoring the electrical conductivity (EC), water content and temperature of the soil, the sensor enables farmers to maximize the yield and quality of crops while minimizing resources such as water and fertilizers.
  • These EC measurements are not affected by soil moisture content, thereby eliminating uncertainty in the soil and contributing to improving crop quality and yield by optimizing fertilizers.
  • As well as monitoring soil conditions, the robust and reliable sensor can monitor the water quality of rivers and lakes.

Generational Equity Advises Glacier Glove in its Sale to Elvisridge Capital

Retrieved on: 
Friday, May 6, 2022 - 1:00pm
Sports, Other Manufacturing, Finance, Textiles, Consulting, Professional Services, Outdoors, Manufacturing, M&A, Senior, LLC, Equity (finance), Company, Boundedly generated group, BBS, FINS, Acquisition, United States Navy SEALs, EC, Sale, Education, Exploration, GG, Financial services

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, Glacier Outdoor, LLC (dba Glacier Glove) to Elvisridge Capital, LLC.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, Glacier Outdoor, LLC (dba Glacier Glove) to Elvisridge Capital, LLC.
  • Located in Reno, Nevada, Glacier Glove (GG), founded in 1982, manufactures and distributes specialty outdoor activity gloves.
  • Glacier Glove will now join Elvisridge Capitals other fishing-related brands, Blackfin Rods and BBS (FINS Fishing), a fishing line manufacturer.
  • Generational Equity , Generational Capital Markets (member FINRA/SIPC), Generational Wealth Advisors , Generational Consulting Group , and DealForce are part of the Generational Group , which is headquartered in Dallas and is one of the leading M&A advisory firms in North America.